Transformative personalized vascular disrupting cancer immunotherapy
变革性个性化血管破坏性癌症免疫疗法
基本信息
- 批准号:8147710
- 负责人:
- 金额:$ 61.51万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-09-24 至 2015-08-31
- 项目状态:已结题
- 来源:
- 关键词:AcuteAffinityAngiogenesis InhibitorsAntibodiesAreaAutologousAvidityBackBlood VesselsCD27 AntigensCD28 geneCD3 AntigensCancer DetectionCancer PatientCell TherapyClinicCollaborationsCytotoxic T-LymphocytesDetectionDevelopmentEndothelin B ReceptorEndotheliumEngineeringEvaluationGlutamate Carboxypeptidase IIGraft RejectionHSV-Tk GeneHerpesvirus 1HumanImageImmunotherapyIn VitroLabelLentivirus VectorLifeLongevityLymphocyteMalignant NeoplasmsMalignant neoplasm of ovaryMembrane ProteinsModelingMonitorMusNormal tissue morphologyPatientsPositron-Emission TomographyPrevalencePublic HealthQuality of lifeRadiolabeledReagentReporterSafetySignal TransductionSpecificitySurfaceT-Cell ActivationT-LymphocyteTestingTherapeuticTimeToxic effectXenograft Modelanti-cancer therapeuticbasecancer immunotherapycancer therapycancer typecombinatorialdesignextracellularimprovedin vivokillingslong term memorymouse modelmutantneoplastic cellneutralizing antibodynovelnovel strategiesradiotracerresearch studyresponsesuicide genetooltraffickingtumor
项目摘要
DESCRIPTION (provided by applicant): While the majority of anticancer therapeutic efforts are designed to directly target tumor cells, there is a strong rationale for targeting the tumor vasculature (TV) instead. The development of vascular-specific tools for therapy has been hindered by (a) the paucity of targets, (b) lack of reagents with optimal affinity and specificity, and (c) their short-lived action due to rapid clearance and/or development of neutralizing antibodies. This proposal aims to solve current limitations in the field of cancer vascular therapy and generate a novel powerful and personalized approach of autologous adoptive vascular disrupting lymphocyte immunotherapy applicable to most tumor types. T cells will be engineered with lentiviral vectors to express chimeric immunoreceptors (CIRs), fusion molecules comprising an extracellular single chain variable fragment (scFv) antibody domain and intracytoplasmic CD3, CD28 and 4-1BB signaling domains for robust T-cell activation. Patient-derived lymphocytes will be genetically reprogrammed to recognize, get activated by and destroy specifically the tumor vasculature. This approach combines the sensitivity and power of cytotoxic T cells with the specificity of scFv, and will unleash on the tumor vasculature the power of acute transplant rejection. Besides specificity and safety, this approach offers durability and long-term memory. CIRs already developed against the tumor vascular surface proteins TEM1, TEM7R and PSMA will be used to validate the approach, while scFv against additional tumor vascular targets identified by the PI's lab and others will be developed. The successful completion of the project will bring to the clinic combinations of modular CIRs for personalized vascular immunotherapy for most common and most recalcitrant tumors. Safety will be maximized by requiring simultaneous recognition of two distinct tumor vascular antigens for T cell activation, by physically separating CD3 from CD28/4-1BB domains in two distinct CIRs, each recognizing a different tumor vascular target. The likelihood of both targets to be co-expressed in normal tissues is negligible, thereby maximizing the therapeutic window. Additional safety will be provided by the integration of a suicide gene in engineered T cells, which will also allow developing PET imaging to track T cell trafficking in real time in vivo. The parallel development of PET imaging capable of visualizing the tumor vasculature targets with the same scFv used in CIR will enable us to select the appropriate combinations of CIRs for personalized therapy and to monitor therapy. The impact of this approach could be transforming, given the power of tumor vascular disruption and its applicability across a wide range of targets shared by most common cancer types. The proposed approach can feasibly reach the clinic to deliver highly personalized cancer therapy of unparalleled power.
描述(由申请人提供):虽然大多数抗癌治疗工作旨在直接靶向肿瘤细胞,但靶向肿瘤血管系统(TV)有很强的理由。用于治疗的血管特异性工具的开发受到以下因素的阻碍:(a)靶点的缺乏,(B)缺乏具有最佳亲和力和特异性的试剂,以及(c)由于中和抗体的快速清除和/或产生而导致的其短暂作用。该提案旨在解决目前癌症血管治疗领域的局限性,并产生一种适用于大多数肿瘤类型的自体过继血管破坏淋巴细胞免疫治疗的新的强大和个性化的方法。T细胞将用慢病毒载体工程化以表达嵌合免疫受体(CIR),融合分子包含细胞外单链可变片段(scFv)抗体结构域和胞质内CD 3、CD 28和4-1BB信号传导结构域,用于稳健的T细胞活化。患者来源的淋巴细胞将被基因重编程以识别肿瘤血管,被肿瘤血管激活并特异性破坏肿瘤血管。这种方法将细胞毒性T细胞的敏感性和能力与scFv的特异性相结合,并将在肿瘤血管系统上释放急性移植排斥的能力。除了特异性和安全性外,这种方法还具有耐用性和长期记忆性。已经针对肿瘤血管表面蛋白TEM 1、TEM 7 R和PSMA开发的CIR将用于验证该方法,而针对PI实验室和其他人鉴定的其他肿瘤血管靶点的scFv将被开发。该项目的成功完成将为临床带来模块化CIR的组合,用于最常见和最难治疗的肿瘤的个性化血管免疫治疗。通过需要同时识别两种不同的肿瘤血管抗原以激活T细胞,通过在两种不同的CIR中将CD 3与CD 28/4-1BB结构域物理分离,每种CIR识别不同的肿瘤血管靶标,将安全性最大化。两种靶标在正常组织中共表达的可能性可以忽略不计,从而最大化治疗窗口。将自杀基因整合到工程化T细胞中将提供额外的安全性,这也将允许开发PET成像以在体内真实的时间跟踪T细胞运输。能够用CIR中使用的相同scFv可视化肿瘤脉管系统靶标的PET成像的平行开发将使我们能够选择用于个性化治疗的CIR的适当组合并监测治疗。这种方法的影响可能会改变,考虑到肿瘤血管破坏的力量及其在大多数常见癌症类型所共有的广泛靶点上的适用性。所提出的方法可以切实可行地到达诊所,以提供无与伦比的高度个性化的癌症治疗。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(1)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
GEORGE COUKOS其他文献
GEORGE COUKOS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('GEORGE COUKOS', 18)}}的其他基金
Vaccine-Dac/Bev Combinatorial Therapy in Ovarian Cancer
卵巢癌疫苗-Dac/Bev 联合治疗
- 批准号:
8189152 - 财政年份:2011
- 资助金额:
$ 61.51万 - 项目类别:
Vaccine-Dac/Bev Combinatorial Therapy in Ovarian Cancer
卵巢癌疫苗-Dac/Bev 联合治疗
- 批准号:
8294558 - 财政年份:2011
- 资助金额:
$ 61.51万 - 项目类别:
Transformative personalized vascular disrupting cancer immunotherapy
变革性个性化血管破坏性癌症免疫疗法
- 批准号:
8539346 - 财政年份:2010
- 资助金额:
$ 61.51万 - 项目类别:
Transformative personalized vascular disrupting cancer immunotherapy
变革性个性化血管破坏性癌症免疫疗法
- 批准号:
8312724 - 财政年份:2010
- 资助金额:
$ 61.51万 - 项目类别:
Transformative personalized vascular disrupting cancer immunotherapy
变革性个性化血管破坏性癌症免疫疗法
- 批准号:
8712194 - 财政年份:2010
- 资助金额:
$ 61.51万 - 项目类别:
Phase I/II Randomized Tiral of Adoptive Lymphocyte Transfer in Ovarian Cancer
卵巢癌过继性淋巴细胞移植的 I/II 期随机试验
- 批准号:
8696861 - 财政年份:2008
- 资助金额:
$ 61.51万 - 项目类别:
Phase I/II Randomized Tiral of Adoptive Lymphocyte Transfer in Ovarian Cancer
卵巢癌过继性淋巴细胞移植的 I/II 期随机试验
- 批准号:
7689383 - 财政年份:2008
- 资助金额:
$ 61.51万 - 项目类别:
Phase I/II Randomized Tiral of Adoptive Lymphocyte Transfer in Ovarian Cancer
卵巢癌过继性淋巴细胞移植的 I/II 期随机试验
- 批准号:
7568096 - 财政年份:2008
- 资助金额:
$ 61.51万 - 项目类别:
相似海外基金
Construction of affinity sensors using high-speed oscillation of nanomaterials
利用纳米材料高速振荡构建亲和传感器
- 批准号:
23H01982 - 财政年份:2023
- 资助金额:
$ 61.51万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Affinity evaluation for development of polymer nanocomposites with high thermal conductivity and interfacial molecular design
高导热率聚合物纳米复合材料开发和界面分子设计的亲和力评估
- 批准号:
23KJ0116 - 财政年份:2023
- 资助金额:
$ 61.51万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Development of High-Affinity and Selective Ligands as a Pharmacological Tool for the Dopamine D4 Receptor (D4R) Subtype Variants
开发高亲和力和选择性配体作为多巴胺 D4 受体 (D4R) 亚型变体的药理学工具
- 批准号:
10682794 - 财政年份:2023
- 资助金额:
$ 61.51万 - 项目类别:
Platform for the High Throughput Generation and Validation of Affinity Reagents
用于高通量生成和亲和试剂验证的平台
- 批准号:
10598276 - 财政年份:2023
- 资助金额:
$ 61.51万 - 项目类别:
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233343 - 财政年份:2023
- 资助金额:
$ 61.51万 - 项目类别:
Standard Grant
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233342 - 财政年份:2023
- 资助金额:
$ 61.51万 - 项目类别:
Standard Grant
Molecular mechanisms underlying high-affinity and isotype switched antibody responses
高亲和力和同种型转换抗体反应的分子机制
- 批准号:
479363 - 财政年份:2023
- 资助金额:
$ 61.51万 - 项目类别:
Operating Grants
Deconstructed T cell antigen recognition: Separation of affinity from bond lifetime
解构 T 细胞抗原识别:亲和力与键寿命的分离
- 批准号:
10681989 - 财政年份:2023
- 资助金额:
$ 61.51万 - 项目类别:
CAREER: Engineered Affinity-Based Biomaterials for Harnessing the Stem Cell Secretome
职业:基于亲和力的工程生物材料用于利用干细胞分泌组
- 批准号:
2237240 - 财政年份:2023
- 资助金额:
$ 61.51万 - 项目类别:
Continuing Grant
ADVANCE Partnership: Leveraging Intersectionality and Engineering Affinity groups in Industrial Engineering and Operations Research (LINEAGE)
ADVANCE 合作伙伴关系:利用工业工程和运筹学 (LINEAGE) 领域的交叉性和工程亲和力团体
- 批准号:
2305592 - 财政年份:2023
- 资助金额:
$ 61.51万 - 项目类别:
Continuing Grant